|
CH686761A5
(de)
|
1993-05-27 |
1996-06-28 |
Sandoz Ag |
Galenische Formulierungen.
|
|
BE1009856A5
(fr)
*
|
1995-07-14 |
1997-10-07 |
Sandoz Sa |
Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
|
|
CA2230748C
(en)
*
|
1997-03-14 |
2010-08-03 |
American Home Products Corporation |
Rapamycin formulations for oral administration
|
|
AU749623B2
(en)
*
|
1998-03-26 |
2002-06-27 |
Astellas Pharma Inc. |
Sustained release preparations
|
|
JP3718341B2
(ja)
|
1998-05-12 |
2005-11-24 |
信越化学工業株式会社 |
低置換度ヒドロキシプロピルセルロースとその製造方法
|
|
US6350786B1
(en)
*
|
1998-09-22 |
2002-02-26 |
Hoffmann-La Roche Inc. |
Stable complexes of poorly soluble compounds in ionic polymers
|
|
US20060240070A1
(en)
*
|
1998-09-24 |
2006-10-26 |
Cromack Keith R |
Delivery of highly lipophilic agents via medical devices
|
|
AU2003200370B2
(en)
*
|
1998-12-07 |
2005-10-27 |
Novartis Ag |
Stabilization of macrolides
|
|
GB9826882D0
(en)
*
|
1998-12-07 |
1999-01-27 |
Novartis Ag |
Organic compounds
|
|
WO2000067773A2
(en)
|
1999-05-10 |
2000-11-16 |
Novartis Ag |
Combinations of immunosupressive agents for the treatment or prevention of graft rejections
|
|
EP1054019A1
(en)
*
|
1999-05-18 |
2000-11-22 |
Shin-Etsu Chemical Co., Ltd. |
Low-substituted hydroxypropyl cellulose
|
|
MXPA02001857A
(es)
|
1999-08-24 |
2003-07-14 |
Cellgate Inc |
Composiciones y metodos para incrementar la entrega de drogas a traves y dentro de tejidos epiteliales.
|
|
US20070032853A1
(en)
|
2002-03-27 |
2007-02-08 |
Hossainy Syed F |
40-O-(2-hydroxy)ethyl-rapamycin coated stent
|
|
US6680069B1
(en)
|
1999-11-09 |
2004-01-20 |
Shin-Etsu Chemical Co., Ltd. |
Low-substituted hydroxypropyl cellulose and process for manufacturing the same
|
|
US7364752B1
(en)
|
1999-11-12 |
2008-04-29 |
Abbott Laboratories |
Solid dispersion pharamaceutical formulations
|
|
CA2359945C
(en)
|
1999-11-12 |
2011-04-26 |
Abbott Laboratories |
Inhibitors of crystallization in a solid dispersion
|
|
RU2264405C2
(ru)
*
|
1999-12-06 |
2005-11-20 |
Новартис Аг |
40-o-(2-гидрокси)этилрапамицин в кристаллической несольватированной форме, фармацевтическая композиция, содержащая такой макролид в качестве действующего вещества, и способ его получения
|
|
JP3552160B2
(ja)
|
2000-01-14 |
2004-08-11 |
信越化学工業株式会社 |
低置換度ヒドロキシプロピルセルロース粒子の形成方法
|
|
IL134701A0
(en)
|
2000-02-23 |
2001-04-30 |
J P M E D Ltd |
Homogeneous solid matrix containing vegetable proteins
|
|
DE10026698A1
(de)
*
|
2000-05-30 |
2001-12-06 |
Basf Ag |
Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
|
|
US20040018228A1
(en)
*
|
2000-11-06 |
2004-01-29 |
Afmedica, Inc. |
Compositions and methods for reducing scar tissue formation
|
|
AU2002256507A1
(en)
*
|
2001-05-09 |
2002-11-18 |
Novartis Ag |
Methods for selective immunomodulation using pimecrolimus
|
|
US20040137066A1
(en)
*
|
2001-11-26 |
2004-07-15 |
Swaminathan Jayaraman |
Rationally designed therapeutic intravascular implant coating
|
|
US6641611B2
(en)
|
2001-11-26 |
2003-11-04 |
Swaminathan Jayaraman |
Therapeutic coating for an intravascular implant
|
|
AU2006218279B2
(en)
*
|
2001-09-28 |
2009-12-10 |
Novartis Ag |
Pharmaceutical compositions comprising colloidal silicon dioxide
|
|
GB0123400D0
(en)
*
|
2001-09-28 |
2001-11-21 |
Novartis Ag |
Organic compounds
|
|
US6939376B2
(en)
|
2001-11-05 |
2005-09-06 |
Sun Biomedical, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
|
US7682387B2
(en)
|
2002-04-24 |
2010-03-23 |
Biosensors International Group, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
|
BR0307516A
(pt)
*
|
2002-02-01 |
2004-12-07 |
Pfizer Prod Inc |
Formas de dosagem de liberação imediata contendo dispersões de uma droga sólida
|
|
ES2305434T3
(es)
|
2002-02-01 |
2008-11-01 |
Pfizer Products Inc. |
Composiciones framaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas.
|
|
AU2003210787B2
(en)
|
2002-02-01 |
2009-04-23 |
Medinol Ltd. |
Phosphorus-containing compounds & uses thereof
|
|
JP3956114B2
(ja)
*
|
2002-06-28 |
2007-08-08 |
インターナショナル・ビジネス・マシーンズ・コーポレーション |
表示制御方法、これを用いたプログラム、情報処理装置及び光学式文字読み取り装置
|
|
BR0316279A
(pt)
*
|
2002-11-15 |
2005-10-11 |
Novartis Ag |
Compostos orgânicos
|
|
AR043504A1
(es)
*
|
2003-03-17 |
2005-08-03 |
Novartis Ag |
Composiciones farmaceuticas que comprenden rapamicina para el tratamiento de enfermedades inflamatorias
|
|
US7160867B2
(en)
|
2003-05-16 |
2007-01-09 |
Isotechnika, Inc. |
Rapamycin carbohydrate derivatives
|
|
US20050118344A1
(en)
|
2003-12-01 |
2005-06-02 |
Pacetti Stephen D. |
Temperature controlled crimping
|
|
US20060177500A1
(en)
*
|
2003-07-09 |
2006-08-10 |
Hee-Jong Shin |
Solid dispersion of tacrolimus
|
|
CA2532931A1
(en)
*
|
2003-08-04 |
2005-02-10 |
Pfizer Products Inc. |
Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
|
|
US8377952B2
(en)
*
|
2003-08-28 |
2013-02-19 |
Abbott Laboratories |
Solid pharmaceutical dosage formulation
|
|
US8025899B2
(en)
|
2003-08-28 |
2011-09-27 |
Abbott Laboratories |
Solid pharmaceutical dosage form
|
|
AU2004270154A1
(en)
*
|
2003-09-03 |
2005-03-17 |
Wyeth |
Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same
|
|
WO2005027906A1
(en)
|
2003-09-18 |
2005-03-31 |
Macusight, Inc. |
Transscleral delivery
|
|
US7780973B2
(en)
*
|
2003-12-15 |
2010-08-24 |
Ethicon Endo-Surgery, Inc. |
Method and device for minimally invasive implantation of biomaterial
|
|
US20050142161A1
(en)
*
|
2003-12-30 |
2005-06-30 |
Freeman Lynetta J. |
Collagen matrix for soft tissue augmentation
|
|
RU2006122517A
(ru)
*
|
2004-01-08 |
2008-02-20 |
Вайет (Us) |
Фармацевтический состав для прямого прессования, предназначенный для перорального введения cci-779
|
|
CA2553573A1
(en)
*
|
2004-01-29 |
2005-08-11 |
Eisai R & D Management Co., Ltd. |
Method for stabilizing macrolide compound
|
|
ES2909080T3
(es)
|
2004-04-23 |
2022-05-05 |
Cydex Pharmaceuticals Inc |
Formulación de DPI que contiene sulfoalquil éter ciclodextrina
|
|
DE602005024012D1
(de)
|
2004-08-27 |
2010-11-18 |
Cordis Corp |
Lösungsmittelfreies amorphes rapamycin
|
|
WO2006039237A1
(en)
*
|
2004-09-29 |
2006-04-13 |
Cordis Corporation |
Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
|
|
US20060088591A1
(en)
*
|
2004-10-22 |
2006-04-27 |
Jinghua Yuan |
Tablets from a poorly compressible substance
|
|
KR100678824B1
(ko)
*
|
2005-02-04 |
2007-02-05 |
한미약품 주식회사 |
용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물
|
|
US8663639B2
(en)
|
2005-02-09 |
2014-03-04 |
Santen Pharmaceutical Co., Ltd. |
Formulations for treating ocular diseases and conditions
|
|
GB2438544A
(en)
|
2005-02-09 |
2007-11-28 |
Cooper Internat Corp |
Liquid formulations for treatment of diseases or conditions
|
|
AU2006222409A1
(en)
*
|
2005-03-08 |
2006-09-14 |
Lifecycle Pharma A/S |
Pharmaceutical compositions comprising sirolimus and/or an analogue thereof
|
|
WO2006102359A2
(en)
*
|
2005-03-23 |
2006-09-28 |
Abbott Laboratories |
Delivery of highly lipophilic agents via medical devices
|
|
US20060240108A1
(en)
*
|
2005-04-26 |
2006-10-26 |
Bernard Bobby L |
Cellulosic films incorporating a pharmaceutically acceptable plasticizer with enhanced wettability
|
|
DE102005026755A1
(de)
*
|
2005-06-09 |
2006-12-14 |
Basf Ag |
Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
|
|
US7629331B2
(en)
|
2005-10-26 |
2009-12-08 |
Cydex Pharmaceuticals, Inc. |
Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
|
|
EP2662082A1
(en)
|
2005-11-14 |
2013-11-13 |
Ariad Pharmaceuticals, Incorporated |
Administration of mTOR inhibitors
|
|
US7700614B2
(en)
|
2005-12-14 |
2010-04-20 |
Abbott Laboratories |
One pot synthesis of tetrazole derivatives of rapamycin
|
|
CA2635797C
(en)
|
2006-02-09 |
2015-03-31 |
Macusight, Inc. |
Stable formulations, and methods of their preparation and use
|
|
CN101443004B
(zh)
|
2006-03-23 |
2013-03-06 |
参天制药株式会社 |
用于与血管通透性有关的疾病或病症的制剂
|
|
US7883855B2
(en)
|
2006-07-21 |
2011-02-08 |
Abbott Laboratories |
Immunosuppressant drug extraction reagent for immunoassays
|
|
US20080138405A1
(en)
*
|
2006-12-06 |
2008-06-12 |
Raheja Praveen |
Sirolimus nanodispersion
|
|
ES2393135T3
(es)
|
2006-12-29 |
2012-12-18 |
Abbott Laboratories |
Ensayo mejorado para fármacos inmunosupresores
|
|
WO2008082984A2
(en)
|
2006-12-29 |
2008-07-10 |
Abbott Laboratories |
Non-denaturing lysis reagent for use with capture-in-solution immunoassay
|
|
WO2008082979A2
(en)
|
2006-12-29 |
2008-07-10 |
Abbott Laboratories |
Diagnostic test for the detection of a molecule or drug in whole blood
|
|
US7914999B2
(en)
|
2006-12-29 |
2011-03-29 |
Abbott Laboratories |
Non-denaturing lysis reagent
|
|
EP1952807A1
(en)
*
|
2007-01-24 |
2008-08-06 |
LEK Pharmaceuticals D.D. |
Sirolimus formulation
|
|
AU2009226019C1
(en)
|
2008-03-20 |
2014-02-20 |
Virun, Inc. |
Emulsions including a PEG-derivative of tocopherol
|
|
SA109300195B1
(ar)
|
2008-03-28 |
2013-04-20 |
Astrazeneca Ab |
تركيبة صيدلانية جديدة مضادة للسرطان
|
|
EP2365802B1
(en)
|
2008-11-11 |
2017-08-02 |
The Board of Regents,The University of Texas System |
Microcapsules of rapamycin and use for treating cancer
|
|
FR2943539B1
(fr)
|
2009-03-31 |
2011-07-22 |
Ethypharm Sa |
Composition pharmaceutique comprenant un macrolide immunosuppresseur de la famille des limus.
|
|
US8728516B2
(en)
*
|
2009-04-30 |
2014-05-20 |
Abbvie Inc. |
Stabilized lipid formulation of apoptosis promoter
|
|
TWI471321B
(zh)
|
2009-06-08 |
2015-02-01 |
亞培公司 |
Ｂｃｌ－２族群抑制劑之口服醫藥劑型
|
|
TWI532484B
(zh)
*
|
2009-06-08 |
2016-05-11 |
艾伯維有限公司 |
包含凋亡促進劑之固態分散劑
|
|
US9283211B1
(en)
|
2009-11-11 |
2016-03-15 |
Rapamycin Holdings, Llc |
Oral rapamycin preparation and use for stomatitis
|
|
US20170079962A1
(en)
|
2009-11-11 |
2017-03-23 |
Rapamycin Holdings, Llc |
Oral Rapamycin Preparation and Use for Stomatitus
|
|
CA2780177A1
(en)
*
|
2009-12-22 |
2011-06-30 |
Abbott Laboratories |
Abt-263 capsule
|
|
CN103037708B
(zh)
|
2010-03-23 |
2015-05-20 |
维尔恩公司 |
含有蔗糖脂肪酸酯的纳米乳液
|
|
RU2585489C2
(ru)
|
2010-04-27 |
2016-05-27 |
Рош Гликарт Аг |
КОМБИНИРОВАННАЯ ТЕРАПИЯ АФУКОЗИЛИРОВАННЫМ АНТИТЕЛОМ CD20 И ИНГИБИТОРОМ mTOR
|
|
IT1400977B1
(it)
*
|
2010-07-01 |
2013-07-05 |
Euticals Spa |
Nuovi complessi di inclusione farmaceutici, solidi, solubili in acqua e le loro soluzioni acquose per uso orale, oftalmico, topico o parenterale, contenenti un macrolide ed alcune ciclodestrine.
|
|
EP2632436B1
(en)
|
2010-10-29 |
2018-08-29 |
Abbvie Inc. |
Solid dispersions containing an apoptosis-inducing agent
|
|
UA113500C2
(xx)
|
2010-10-29 |
2017-02-10 |
|
Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
|
|
NZ708508A
(en)
|
2010-11-23 |
2016-06-24 |
Abbvie Bahamas Ltd |
Methods of treatment using selective bcl-2 inhibitors
|
|
JP6141188B2
(ja)
|
2010-11-23 |
2017-06-07 |
アッヴィ・インコーポレイテッド |
アポトーシス誘導剤の塩および結晶の形態
|
|
WO2012092421A2
(en)
|
2010-12-30 |
2012-07-05 |
Surmodics, Inc. |
Composition for intravascular delivery of therapeutic composition
|
|
EP2702173A1
(en)
|
2011-04-25 |
2014-03-05 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
|
US20120303115A1
(en)
*
|
2011-05-25 |
2012-11-29 |
Dadino Ronald C |
Expandable devices coated with a rapamycin composition
|
|
JP2014516075A
(ja)
|
2011-06-06 |
2014-07-07 |
シェブロン フィリップス ケミカル カンパニー エルピー |
癌治療のためのメタロセン化合物の使用
|
|
KR101151890B1
(ko)
*
|
2011-08-11 |
2012-05-31 |
동아제약주식회사 |
안정화 및 가용화된 시롤리무스 유도체 조성물의 제조방법
|
|
WO2013022201A1
(en)
*
|
2011-08-11 |
2013-02-14 |
Dong-A Pharm. Co., Ltd. |
Process of preparing a stabilized and solubilized formulation of sirolimus derivatives
|
|
PH12014500746A1
(en)
|
2011-10-06 |
2019-07-17 |
Novartis Ag |
Pharmaceutical compositions comprising 40 - o - ( 2 - hydroxy) ethyl - rapamycin
|
|
EP2594260A1
(en)
*
|
2011-11-18 |
2013-05-22 |
LEK Pharmaceuticals d.d. |
Solid preparations comprising sirolimus with desired bioavailability and method for its preparation
|
|
US8912215B2
(en)
*
|
2011-12-13 |
2014-12-16 |
Everon Biosciences, Inc. |
Rapamycin composition
|
|
KR200477251Y1
(ko)
*
|
2011-12-30 |
2015-05-22 |
엘에스산전 주식회사 |
배선용 차단기의 주 접점 위치 표시 기구
|
|
CN103585122B
(zh)
*
|
2012-08-17 |
2017-12-05 |
山东新时代药业有限公司 |
一种含依维莫司的片剂及其制备方法
|
|
WO2014059295A1
(en)
|
2012-10-12 |
2014-04-17 |
The Board Of Regents Of The University Of Texas System |
Use of mtor inhibitors to treat vascular cognitive impairment
|
|
US9610385B2
(en)
|
2013-03-07 |
2017-04-04 |
Abbott Cardiovascular Systems Inc. |
Method of fabricating an implantable medical device comprising a rapamycin derivative
|
|
US20160030401A1
(en)
|
2013-03-13 |
2016-02-04 |
The Board Of Regents Of The University Of Texas System |
Use of mtor inhibitors for prevention of intestinal polyp growth and cancer
|
|
US20140275082A1
(en)
|
2013-03-14 |
2014-09-18 |
Abbvie Inc. |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
|
TW201503912A
(zh)
*
|
2013-03-19 |
2015-02-01 |
Novartis Ag |
包含癌莫事（ｅｖｅｒｏｌｉｍｕｓ）之醫藥組合物
|
|
US10682415B2
(en)
|
2013-07-22 |
2020-06-16 |
Wisconsin Alumni Research Foundation |
Thermogel formulation for combination drug delivery
|
|
CN113768881A
(zh)
|
2013-10-08 |
2021-12-10 |
人工智能治疗公司 |
用于治疗淋巴管平滑肌瘤病的雷帕霉素
|
|
JP2016537345A
(ja)
|
2013-11-13 |
2016-12-01 |
ノバルティス アーゲー |
免疫応答を増強するためのｍＴＯＲ阻害剤
|
|
CN103610646B
(zh)
*
|
2013-12-05 |
2015-07-15 |
江苏奥赛康药业股份有限公司 |
一种含依维莫司的组合物及其制备方法和含有这一组合物的药物制剂
|
|
CA3225453A1
(en)
|
2013-12-19 |
2015-06-25 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
|
EP3087101B1
(en)
|
2013-12-20 |
2024-06-05 |
Novartis AG |
Regulatable chimeric antigen receptor
|
|
CN104721158B
(zh)
*
|
2013-12-24 |
2018-01-30 |
正大天晴药业集团股份有限公司 |
一种稳定的依维莫司片剂
|
|
US9700544B2
(en)
|
2013-12-31 |
2017-07-11 |
Neal K Vail |
Oral rapamycin nanoparticle preparations
|
|
CA3206208A1
(en)
|
2013-12-31 |
2015-07-09 |
Rapamycin Holdings, Llc |
Oral rapamycin nanoparticle preparations and use
|
|
BR112016018365A2
(pt)
|
2014-02-11 |
2017-08-08 |
Lam Therapeutics Inc |
Formulação farmacêutica aerossol, na forma de um pó seco para distribuição pulmonar, seus usos, forma de dosagem unitária, embalagem ou kit farmacêutico, e dispositivo de distribuição de pó seco
|
|
US10307371B2
(en)
|
2014-02-11 |
2019-06-04 |
AI Therapeutics, Inc. |
Rapamycin for the treatment of lymphangioleiomyomatosis
|
|
WO2015142675A2
(en)
|
2014-03-15 |
2015-09-24 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
|
WO2015149001A1
(en)
|
2014-03-27 |
2015-10-01 |
The Brigham And Women's Hospital, Inc. |
Metabolically-activated drug conjugates to overcome resistance in cancer therapy
|
|
CA2944075C
(en)
|
2014-04-04 |
2022-06-28 |
Lam Therapeutics, Inc. |
An inhalable rapamycin formulation for treating age-related conditions
|
|
FI3888674T3
(fi)
|
2014-04-07 |
2024-07-02 |
Novartis Ag |
Syövän hoito käyttäen kimeeristä anti-cd19-antigeenireseptoria
|
|
MX2016015569A
(es)
|
2014-06-02 |
2017-04-25 |
Children´S Medical Center Corp |
Metodos y composiciones para inmunomodulacion.
|
|
BR112017001242A2
(pt)
|
2014-07-21 |
2017-12-05 |
Novartis Ag |
tratamento de câncer usando um receptor antigênico quimérico a cd33
|
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
US20170209492A1
(en)
|
2014-07-31 |
2017-07-27 |
Novartis Ag |
Subset-optimized chimeric antigen receptor-containing t-cells
|
|
JP6919118B2
(ja)
|
2014-08-14 |
2021-08-18 |
ノバルティス アーゲー |
ＧＦＲα−４キメラ抗原受容体を用いる癌の治療
|
|
MY189028A
(en)
|
2014-08-19 |
2022-01-20 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
|
CA2961636A1
(en)
|
2014-09-17 |
2016-03-24 |
Boris ENGELS |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
WO2016057712A1
(en)
|
2014-10-07 |
2016-04-14 |
Lam Therapeutics, Inc. |
An inhalable rapamycin formulation for the treatment of pulmonary hypertension
|
|
CN106973568B
(zh)
|
2014-10-08 |
2021-07-23 |
诺华股份有限公司 |
预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途
|
|
MA40910A
(fr)
|
2014-11-07 |
2017-09-12 |
Civitas Therapeutics Inc |
Poudres de rapamycine pour administration pulmonaire
|
|
WO2016130645A1
(en)
|
2015-02-10 |
2016-08-18 |
Lam Therapeutics, Inc. |
Rapamycin for the treatment of lymphangioleiomyomatosis
|
|
WO2016135740A1
(en)
|
2015-02-23 |
2016-09-01 |
Natco Pharma Limited |
Process for preparing stable oral compositions of everolimus
|
|
ES2876974T3
(es)
|
2015-04-07 |
2021-11-15 |
Novartis Ag |
Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina
|
|
CN108473957B
(zh)
|
2015-04-17 |
2024-07-16 |
诺华股份有限公司 |
改善嵌合抗原受体表达细胞的功效和扩增的方法
|
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
CN107847491A
(zh)
|
2015-05-20 |
2018-03-27 |
诺华公司 |
依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合
|
|
WO2016198983A1
(en)
|
2015-06-09 |
2016-12-15 |
Bend Research Inc. |
Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
|
|
US10383860B2
(en)
|
2015-07-28 |
2019-08-20 |
Nippon Kayaku Kabushiki Kaisha |
Pharmaceutical composition comprising rapamycin or derivative thereof, and method for producing the same
|
|
WO2017038612A1
(ja)
*
|
2015-08-28 |
2017-03-09 |
日本化薬株式会社 |
ラパマイシン又はその誘導体を含有する医薬組成物
|
|
JP6793652B2
(ja)
*
|
2015-09-03 |
2020-12-02 |
日本化薬株式会社 |
ラパマイシン又はその誘導体を含有する医薬組成物
|
|
JP6855470B2
(ja)
|
2016-05-27 |
2021-04-07 |
日本化薬株式会社 |
ラパマイシン又はその誘導体を含有する医薬組成物
|
|
US11365252B2
(en)
|
2016-07-20 |
2022-06-21 |
University Of Utah Research Foundation |
CD229 CAR T cells and methods of use thereof
|
|
US20190231755A1
(en)
*
|
2016-10-04 |
2019-08-01 |
Nippon Kayaku Kabushiki Kaisha |
Method for producing solid dispersion comprising rapamycin derivative
|
|
EP3523331A1
(en)
|
2016-10-07 |
2019-08-14 |
Novartis AG |
Chimeric antigen receptors for the treatment of cancer
|
|
CN110114070A
(zh)
|
2016-11-23 |
2019-08-09 |
诺华公司 |
使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法
|
|
CN107080738A
(zh)
*
|
2017-04-26 |
2017-08-22 |
四川制药制剂有限公司 |
乙酰螺旋霉素片的制备方法
|
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
EP3624863B1
(en)
|
2017-05-15 |
2021-04-14 |
C.R. Bard, Inc. |
Medical device with drug-eluting coating and intermediate layer
|
|
WO2019157516A1
(en)
|
2018-02-12 |
2019-08-15 |
resTORbio, Inc. |
Combination therapies
|
|
US20210047405A1
(en)
|
2018-04-27 |
2021-02-18 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
US20210396739A1
(en)
|
2018-05-01 |
2021-12-23 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
JP7262581B2
(ja)
|
2018-11-14 |
2023-04-21 |
ルトニックス，インコーポレーテッド |
改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス
|
|
JP7487228B2
(ja)
|
2019-04-08 |
2024-05-20 |
バード・ペリフェラル・バスキュラー・インコーポレーテッド |
改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス
|
|
EP3741367A1
(en)
|
2019-05-21 |
2020-11-25 |
Premark Pharma GmbH |
Treatment of ocular disease
|
|
JPWO2020261619A1
(enExample)
*
|
2019-06-26 |
2020-12-30 |
|
|
|
AU2020410545A1
(en)
*
|
2019-12-19 |
2022-08-11 |
Triviumvet Dac |
Veterinary formulations comprising rapamycin and methods of using the same for treating animal diseases
|
|
WO2023288046A1
(en)
|
2021-07-15 |
2023-01-19 |
President And Fellows Of Harvard College |
Compositions and methods relating to cells with adhered particles
|
|
WO2024209038A1
(en)
|
2023-04-06 |
2024-10-10 |
Premark Pharma Gmbh |
Use of pimecrolimus for the treatment of dry eye in patients characterized by a corneal staining score of 4 or 5 on the oxford grading scale
|